Scientists at Verve Therapeutics in Boston conducted the inaugural human trial of base editing, using the treatment VERVE-101 to deactivate the PCSK9 gene in the liver. The gene regulates ‘bad’ cholesterol, and the one-time injection resulted in a significant LDL reduction of up to 55%. This milestone suggests a potential transformative approach to treat coronary artery disease. However, safety concerns emerged, with two serious adverse events, including a death. The findings, presented at the American Heart Association meeting, indicate both promise and challenges for this ground-breaking gene-editing technique.
Related Posts
EXPLORING THE CONNECTION: Type 2 Diabetes and Migraine Risk in Chinese Populations
A groundbreaking study has delved into the intriguing relationship between type 2 diabetes (T2D) and the risk of migraine among Chinese populations. Migraine, a debilitating neurological disorder, has long been associated with various comorbidities, and emerging evidence suggests a potential connection with diabetes. The study, conducted in Chinese cohorts, sheds light on the complex interplay […]
First-Ever Epstein-Barr Virus Vaccine Shows Strong Immune Response
Scientists at the QIMR Berghofer Medical Research Institute have achieved a groundbreaking advancement in creating the first-ever vaccine against the Epstein-Barr virus (EBV), responsible for infectious mononucleosis and linked to cancer and multiple sclerosis. The vaccine stimulates antibodies and T cells, integral components of the immune system, to combat EBV. It also offers a unique […]
How to write a response to the reviewers of your manuscript
Writing a response letter is tricky. Rarely manuscript does get accepted without some revisions. Once you have got a mail stating revision, it’s not only important to modify the manuscript but also write a comprehensive and clear response letter. The response letter should highlight your efforts way before the comparison between the original and revised manuscript […]